

MARK W. WILSON, MD, PC
330 WEST 58TH STREET, SUITE 313
NEW YORK, NEW YORK 10019

Lumateperone

- Being studied for
 - Schizophrenia
 - Bipolar depression
 - Agitation associated with dementia
- Mechanisms of action
 - Serotonin
 - 5HT_{2a} blocker at low doses
 - Dopamine
 - Mesolimbic/mesocortical DA receptor phosphoprotein modulator
 - D₂ presynaptic partial agonist
 - D₂ postsynaptic antagonist
 - D₁ activation → enhances NMDA- and AMPA-induced currents in medial PFC pyramidal neurons
- 60 mg/d (40% occupancy of striatal D₂ receptors) reduces psychosis